Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.65 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862098 | 0.88 | TRPV1 (0.49) | TRPV1GAK | |
| SCHEMBL1860053 | 0.85 | TRPV1 (0.64) | TRPV1MAPK3MAPK10GAK | |
| SCHEMBL1862218 | 0.82 | TRPV1 (0.64) | TRPV1MAPK3 | |
| SCHEMBL5117433 | 0.81 | TRPV1 (0.66) | TRPV1MAPK3MAPK10GAKDYRK3 | |
| SCHEMBL12629699 | 0.81 | TRPV1 (0.63) | TRPV1MAPK3MAPK10GAKDYRK3 | |
| SCHEMBL5113971 | 0.80 | TRPV1 (0.65) | TRPV1MAPK3MAPK10GAKDYRK3 | |
| SCHEMBL1859233 | 0.80 | TRPV1 (0.62) | TRPV1MAPK3MAPK10GAKDYRK3 | |
| SCHEMBL5929084 | 0.80 | TRPV1 (0.63) | TRPV1MAPK3GAKGSK3AGSK3B | |
| SCHEMBL4362074 | 0.79 | TRPV1 (1.00) | TRPV1MAPK3 | |
| SCHEMBL5929115 | 0.79 | TRPV1 (0.58) | TRPV1MAPK3MAPK10GAKDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885MAPK3 2884/4885MAPK10 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.